UBA1 and prostate carcinoma: Furthermore, Wang et al. identified that UBA1, an E1 ubiquitin-activating enzyme, triggers the degradation by regulating ubiquitination of RNA-binding-base-regulating protein 15 (RBM15), affects the therapeutic effectiveness of docetaxel in chemotherapy-resistant prostate cancer by influencing the stemness and apoptosis of prostate CSCs [136].